ScreenerHero

ABUSArbutus Biopharma Corporation

NAS · US · Healthcare · Biotechnology · arbutusbio.com
5.210USD+4.62%Mkt Cap: 1.03B $P/E: 6.59

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conj…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.03B $
Enterprise Value854.73M $
Revenue (TTM)181.72M $
Gross Profit163.92M $
Net Income (TTM)-33.50M $
Revenue/Share0.9370 USD
Last Price5.210 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees19
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINCA03879J1003
Valuation
P/E (Trailing)6.59
P/E (Forward)-28.86
PEG—
EV/EBITDA5.80
EV/Revenue4.70
P/S5.19
P/B3.64
EPS (TTM)0.76
EPS (Forward)-0.17
52W Range
3.31089% of range5.448
52W High5.448 USD
52W Low3.310 USD
Profitability
Gross Margin90.20%
Oper. Margin-567.16%
EBITDA Margin81.15%
Profit Margin-237.88%
ROE-43.75%
ROA-35.41%
Growth
Revenue Growth-90.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.64M $
CapEx (TTM)—
FCF Margin-44.15%
FCF Yield-7.78%
Net Debt-89.00M $
Net Debt/EBITDA-0.60
Balance Sheet
Debt/Equity0.01
Current Ratio81.42
Quick Ratio81.08
Book Value/Sh1.309 USD
Cash/Share0.4680 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateNov 4, 2010
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.546 USD
Upside (mean)+6.4%
Target Range5.546 USD – 5.546 USD
# Analysts1
Ownership
Shares Out.197.85M
Float122.66M
Insiders20.43%
Institutions72.28%
Short Interest
Short Ratio9.6d
Short % Float15.24%
Short % Out.10.24%
Shares Short20.24M
Short (prev mo.)17.11M
Technical
SMA 504.585 (+13.6%)
SMA 2004.459 (+16.8%)
Beta0.60
S&P 52W Chg18.16%
Avg Vol (30d)2.40M
Avg Vol (10d)1.46M
Technical Indicators
RSI (14)69.9
MACD0.1027
MACD Signal0.0368
MACD Hist.+0.0660
BB Upper5.010 USD
BB Middle4.556 USD
BB Lower4.103 USD
BB Width19.90%
ATR (14)0.2269 USD
Vol Ratio (20d)12.79x